Skip to main content
. 2017 May 1;33(5):410–423. doi: 10.1089/aid.2016.0204

FIG. 1.

FIG. 1.

RV144, VAX003, and VAX004 vaccination schedules and HIV-1 gp120 envelope variable loops 2 and 3 (V2 and V3). (A) RV144, VAX003 and VAX004 vaccination schedules and vaccine antigens; A = ALVAC-HIV (vCP1521), B/B = AIDSVAX® B/B (gp120 MNgD and gp120 GNE8gD–600 μg), B/E = AIDSVAX B/E (gp120 MNgD and gp120 A244gD–600 μg). Visit samples used in study are in bold. In VAX trials immunizations are given at even numbers and odd numbers represent 2 weeks post immunization. (B) Alignments of HIV-1 gp120 envelope variable loops 2 and 3 (V2 and V3); V2 and V3 loops are shown in the top and bottom panel, respectively. Boxed amino acids show differences from reference strain HxB2. Numbers on top of each panel are positions of amino acids based on the HxB2 strain. (C) Percent identity and divergence of gp120 proteins and variable loops 2 and 3 (V2 and V3). gD, glycoprotein D.